Children's Oncology Group's 2013 blueprint for research: Bone tumors
Pediatric Blood & Cancer2012Vol. 60(6), pp. 1009–1015
Citations Over TimeTop 10% of 2012 papers
Abstract
In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.
Related Papers
- → A Blueprint for Sovereign Wealth Fund Best Practices(2009)101 cited
- Clinical Services Blueprint Leaves DITs Short Changed(2009)
- Using internet to come true the management for blueprint of mechanical engineering(2005)
- Research on the Construction of Procedure Blueprint Supporting Environment(2012)
- Building a Regional Voice: Stakeholder Perceptions of the Sacramento Area Council of Governments’ Blueprint Initiative - eScholarship(2007)